Company attributes
Location
CEO
Founder
Pitchbook URL
Legal Name
Icosavax, Inc.
Legal classification
Date Incorporated
2017
Number of Employees (Ranges)
11 – 50
Email Address
careers@icosavax.com0
info@icosavax.com0
media@icosavax.com0
ir@icosavax.com0
Full Address
1930 Boren Ave, Suite 1000 Seattle, WA 981010
1616 Eastlake Avenue East Suite 208 Seattle, WA 98102 United States
CIK Number
Place of Incorporation
Investors
Founded Date
2018
0Total Funding Amount (USD)
385,007,373
Latest Funding Round Date
July 29, 2021
Business Model
Commerce
Stock Symbol
ICVX0
Exchange
Board of Directors
Latest Funding Type
Country
Other attributes
Company Operating Status
Active
Latest Funding Round Amount (USD)
182,000,000
SIC Code
2,8360
Ticker Symbol
ICVX
Icosavax is a biotechnology company in Washington that focuses on developing safe and effective vaccines against infectious diseases. Founded 2017 in Seattle, Washington, United States by David Baker Ph.D, Neil King, Adam Simpson JD, it invests in early stage ventures. It is a developer of computationally designed virus-like particle vaccines that are intended to reduce serious infectious diseases, including Respiratory Syncytial Virus. The vaccine is being developed to protect older people from respiratory syncytial virus (RSV) diseases. The company believes that science and technology can and will continue to improve public health and that preventing infection is preferable to treating illness.
Timeline
No Timeline data yet.
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Further Resources
No Further Resources data yet.
